AR071310A1 - Sulfonamidas - Google Patents

Sulfonamidas

Info

Publication number
AR071310A1
AR071310A1 ARP090101265A ARP090101265A AR071310A1 AR 071310 A1 AR071310 A1 AR 071310A1 AR P090101265 A ARP090101265 A AR P090101265A AR P090101265 A ARP090101265 A AR P090101265A AR 071310 A1 AR071310 A1 AR 071310A1
Authority
AR
Argentina
Prior art keywords
denotes
het
substituted
group
atoms
Prior art date
Application number
ARP090101265A
Other languages
English (en)
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of AR071310A1 publication Critical patent/AR071310A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos para el tratamiento de las enfermedades relacionadas con CXCR3, procedimiento de preparacion, composicion farmacéutica y usos. Reivindicacion 1: Un compuesto de la formula (1) donde A* representa V, un grupo alquileno C1-6 que está substituido o no substituido por Rf, Rg, carbonilo (=O), o por un grupo -C(O)-ORf o -C(O)NRfRg; V representa un grupo -CO-, un grupo lineal o ramificado, alquileno C1-6, o una union; W1, W2 son independientemente una de otra N o CH; W3 representa CR1R2 o un grupo alquileno C1-6 que está substituido o no substituido Rf, Rg, carbonilo (=O), o por un grupo -C(O)-ORf o -C(O)NRfRg; Ra denota Ar o Het; Rb denota Hal, Ar, CN, Het, -NO2, -N(R3)2, -NH-C(O)A, -COOR3, -COOA, -C(O)-NHSO2A, -C(O)-NHSO2Het, -C(O)-NHSO2Ar, Cic, CONHZ, ORf o un grupo -C(O)-NHQRd, -NH-C(O)QRd, -COOH o tetrazolilo u oxadiazolilo, oxadiazolilo substituido hidroxilo, los que pueden todos estar no substituidos o substituidos por alquilo C1-8, o si Ra está substituida por Ar o substituida por Het, también H, o, si Ra está substituida por Het o por Ar, o si Rc es H, F, Br, I, CN, CF3, OCF3, NO2, Het, tetrazol, alquilo C1-6, o alcoxi C1-6, o si W2 es N, o si W1 es N, o si R1 y R2 son alquilo C1-3, o R1 y R2 se construyen juntas con el átomo al cual están unidas a un anillo carbocíclico o heterocíclico que tiene desde 3 hasta 7 átomos, o si V representa un CO o un grupo lineal o ramificado alquileno C2-6, o una union, o si W3 representa a un grupo alquileno C2-5 que está substituido o no substituido por Rf, Rg, carbonilo (=O), o por un grupo -C(O)-ORf o -C(O)NRfRg; o si A* representa un grupo alquileno C2-5 que está substituido o no substituido por Rf, Rg, carbonilo (=O), o por un grupo -C(O)-ORf, -C(O)NRfRg, entonces Rb también denota un grupo -C(O)-NHA, -C(O)NHHet, -C(O)NHQRd o -C(O)-NHAr; Z denota uno de los restos del grupo de formulas (2); A denota a un alquileno lineal o ramificado C1-12, donde uno o mas, preferiblemente 1 hasta 7 átomos H pueden estar reemplazados por Hal, OR3, N(R3)2, Het, Ar, NHCOOR3, COOR3, -CON(R3)2, y donde uno o más grupos CH2- pueden estar reemplazados por O, NR3, OCO, NHCO, SO2, y/o por -CH=CH-, -CsC-, o denota cicloalquilo, cicloalquileno o cicloalquilalquileno que tiene desde 3 hasta 7 átomos C del anillo; R3 denota H, alquilo C1-6 donde 1 o más átomos pueden estar reemplazados por Ar; Rc denota H, Hal, CN, CF3, OCF3, Het, NO2, tetrazol, alquilo C1-6 o alcoxi C1-6, o un resto de formula (3); Q es (CR1R2)p, (CH2)p, (CH2)pSO2(CH2)p', o Rd denota H, Ar, Het o cicloalquilo C3-7; Re denota H, Hal, NH2, NO2, Ar, O-Ar, preferiblemente O-fenilo, Het o cicloalquilo C3-7, o Rf; Rf, Rg son independientemente una de otra H, Ar, Het, O alquilo inferior o Rf y Rg se construyen juntas con el átomo o átomos al cual están unidas, a un anillo carbocíclico o heterocíclico que tiene desde 3 hasta 7 átomos; R1, R2 son independientemente una de otra H, alquilo, alquiloxi, hidroxi, hidroxialquilo, amino, aminoalquilo, alquilamino, alquilaminoalquilo, carboxi, alquiloxi carbonilo, aminocarbonilo o alquilaminocarbonilo, o R1 y R2 se construyen juntas con el átomo o átomos al cual están unidas a un anillo carbocíclico o heterocíclico que tiene desde 3 hasta 7 átomos o R1, R2 son independientemente una de otra H, alquilo C1-3, o R1 y R2 se construyen juntas con el átomo al cual están unidas a un anillo carbocíclico o heterocíclico que tiene desde 3 hasta 7 átomos, o R1 es un alquileno C1-6 unido a Ra; R4 denota H o OR3; Hal denota F, Cl, Br, o I; Ar denota un anillo monocíclico o bicíclico, saturado, no saturado o aromático carbocíclico que tiene desde 6 hasta 14 átomos de carbono, que está no sustituido o monosustituido, disustituido o trisustituido por alquilo C1-8, alcoxi C1-8, Hal, CF3, OCF3, NO2, N(R3)2, COOR3, COR3, SO2N(R3)2, COHet, Het, OHet, OR3, CONH(CH2)pN(R3)2, Cic, SO2N(R3)2, CN, y/o acilo; Het denota un anillo monocíclico o bicíclico, saturado, no saturado o aromático heterocíclico que tiene desde 1 hasta 4 átomos N, O y/o S o una funcion CO, que está no substituida o monosustituida, disustituida o trisustituida por alquilo C1-8, alcoxi C1-8, Hal, CF3, OCF3, NO2, CN, N(R3)2, COOR3, COR3, SO2N(R3)2, COAr, OR3, Ar, CONH(CH2)pN(R3)2, Cic, SO2N(R3)2, Ar, OAr, y/o acilo; Cic denota un cicloalquilo C3-12, que está no sustituido o monosustituido, disustituido, trisustituido por OR3, Hal, CN; p, p' son cada una independientemente una de la otra 0, 1, 2, 3, 4, 5 o 6; s es 0, 1, 2, 3 o 4; y los derivados, solvatos, tautomeros, sales y esteroisomeros de los mismos, farmacéuticamente aceptables, incluyendo las mezclas de los mismos en todas las proporciones.
ARP090101265A 2008-04-11 2009-04-08 Sulfonamidas AR071310A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08154366 2008-04-11
US12460108P 2008-04-17 2008-04-17

Publications (1)

Publication Number Publication Date
AR071310A1 true AR071310A1 (es) 2010-06-09

Family

ID=40039812

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101265A AR071310A1 (es) 2008-04-11 2009-04-08 Sulfonamidas

Country Status (6)

Country Link
US (1) US20110028509A1 (es)
EP (1) EP2265575A2 (es)
AR (1) AR071310A1 (es)
AU (1) AU2009235406A1 (es)
CA (1) CA2720530A1 (es)
WO (1) WO2009124962A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2456435B1 (en) * 2009-07-21 2015-06-24 The Board of Trustees of the Leland Stanford Junior University Heteroaryl benzamides, compositions and methods of use
WO2012047926A2 (en) * 2010-10-04 2012-04-12 The Brigham And Women's Hospital, Inc. Sulfonamide-containing compounds
US9346795B2 (en) 2011-05-25 2016-05-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic Bcl inhibitors
US8710043B2 (en) 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
CA2839703A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2017030987A1 (en) * 2015-08-14 2017-02-23 The Broad Institute, Inc. Compositions and methods for treating multiple myeloma
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
WO2017160832A1 (en) * 2016-03-14 2017-09-21 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521619A1 (en) * 2003-04-11 2004-10-28 Taigen Biotechnology Aminoquinoline compounds
WO2006009876A2 (en) * 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases

Also Published As

Publication number Publication date
WO2009124962A2 (en) 2009-10-15
US20110028509A1 (en) 2011-02-03
AU2009235406A1 (en) 2009-10-15
CA2720530A1 (en) 2009-10-15
EP2265575A2 (en) 2010-12-29
WO2009124962A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
AR071310A1 (es) Sulfonamidas
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR056215A1 (es) Derivados de indol como inhibidores de la proteina activadora de 5-lipoxigenasa (flap), composiciones farmaceuticas que los comprenden y su uso en el tratamiento de trastornos respiratorios e inflamatorios
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR074966A1 (es) Compuestos amino-heterociclicos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR087184A1 (es) Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen
ES2625256T3 (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA
AR086977A1 (es) Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR072227A1 (es) Derivados de triazinona sustituidos
AR076076A1 (es) Compuestos biciclicos y heterociclicos fusionados,composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes
AR090041A1 (es) Aril dihidropiridinona y piperidinona como inhibidores de mgat2
AR071523A1 (es) Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR065133A1 (es) Derivados de tetrahidroisoquinolina, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir enfermedades o trastornos asociados a la actividad de gpr119, tales como diabetes, obesidad y trastornos cardiovasculares, entre otros.
AR072042A1 (es) Compuestos de 2,3,4,5-tetrahidro-1h-pirido(4,3-b)indol y metodos de uso de los mismos
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
AR075050A1 (es) Dicianopiridinas alquilamino-sustituidas
AR039124A1 (es) Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR060609A1 (es) Compuestos inhibidores de proteinquinasas c-fms.
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
AR082844A1 (es) Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos
AR037460A1 (es) Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion
AR083872A1 (es) Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep

Legal Events

Date Code Title Description
FA Abandonment or withdrawal